Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

RegulatoryNegative

AI Analysis

Summary

Vanda Pharmaceuticals publicly calls on the FDA to withdraw a legislative proposal from its FY 2027 Congressional Budget Justification that would extend drug review timelines by eliminating statutory requirements.

Outcome Details

Vanda calls on FDA to withdraw proposal from FY 2027 legislative agenda that would extend drug review timelines

Importance:4/10

Sentiment:

-0.50

regulatory_advocacyFDA_policydrug_review_timelinelegislative_proposal

Related Companies

$VNDA

Read the original article

Published by PR Newswire Pharma on April 9, 2026 3:02 PM

Read Original